Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes
about
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".Hepatitis C eradication with sofosbuvir leads to significant metabolic changes.Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation.Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
P2860
Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@ast
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@en
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@nl
type
label
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@ast
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@en
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@nl
prefLabel
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@ast
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@en
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@nl
P2860
P3181
P356
P1476
Lipid dysregulation in hepatit ...... therapy upon clinical outcomes
@en
P2093
Tracey G Simon
P2860
P304
P3181
P356
10.3748/WJG.V21.I27.8293
P407
P50
P577
2015-07-01T00:00:00Z